Further Research Required for Aortic Valve Reconstruction Procedure, Says NICE

By Staff Writer

August 28, 2023

The National Institute for Health and Care Excellence (NICE) has released new guidelines regarding aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease. Published in August 2023, the guidelines recommend that the procedure should be used only in research until further evidence is obtained.

The procedure has shown promising short-term and medium-term results, with survival rates of around 90% after ten years and only a small proportion of patients needing a second operation within five years. However, NICE highlights the need for long-term evidence, particularly the durability of the valve, as mechanical valve alternatives can last for over 25 years.

The lack of long-term evidence is particularly relevant for younger patients who are expected to live for several more decades with the condition. NICE also emphasises the need to understand how the procedure works and its safety in different demographic groups with aortic valve disease.

Aortic valve disease is a progressive condition that increases cardiac workload, leading to left ventricular hypertrophy and heart failure. The conventional treatment for a significantly diseased aortic valve is surgical replacement with an artificial prosthesis or transcatheter aortic valve implantation (TAVI) with a biological prosthesis.

The aortic valve reconstruction procedure using glutaraldehyde-treated autologous pericardium provides an alternative to mechanical or biological valves, particularly for younger patients. However, NICE notes that this is a complex procedure and should only be performed by cardiac surgeons with special training and experience.

The committee has recommended that details of all patients undergoing the procedure should be recorded in a registry to aid future research and improve understanding of the procedure’s effectiveness and safety.

Reference url

Recent Posts

Navigating Challenges for Small Countries to Access Innovative Medicines

By João L. Carapinha

July 31, 2025

Access to innovative medicines is a pressing issue for patients in smaller European countries. These nations often face significant barriers in obtaining timely and equitable healthcare solutions. The article "Ensuring access to innovative medicines for patients in smaller countries" (linked belo...
Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity
The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...